home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 11/25/20

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - Diagnostic Capabilities Remain of Utmost Importance as Cases Surge Worldwide

FinancialBuzz.com News Commentary New York, NY (11/25/2020) – As of earlier this week, the U.S. has reported more than 12.4 million cases and over 257,600 deaths, according to Johns Hopkins University data. Dr. Anthony Fauci, the National Institute of Allergy and Infectious Disea...
CYDY - CytoDyn Announces Partnership with amfAR to Accelerate HIV Cure Research

 Vyrologix™ (leronlimab) has successfully replicated the CCR5 deficient phenotype in a pre-clinical animal study, and will now initiate HIV cure-focused clinical studies in collaboration with amfAR VANCOUVER, Washington, Nov. 23, 2020 (GLOBE NEWSWIRE) -- CytoDyn...

CYDY - CytoDyn reaches target enrollment for second interim analysis of Phase 3 COVID-19 trial

CytoDyn (CYDY) has reached enrollment of 293 patients in its Phase 3 trial for COVID-19 patients with severe-to-critical symptoms, thereby meeting requested criteria for a second interim efficacy analysis by the Data Safety Monitoring Committee ((DSMC)).The company expects to enroll the remai...

CYDY - CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This Year

Concurrently, CytoDyn is w orking d iligently with the FDA to initiate its Phase 2 COVID-19 Long Hauler T rial , with m ore than 100 volu n teers wanting to enroll VANCOUVER, Washington, Nov. 23, 2020 (GLOBE N...
CYDY - CytoDyn Files Protocol with U.S. FDA for Phase 2 Clinical Trial for COVID-19 Patients with Long-Hauler Symptoms

Rapid Enrollment Expected , As Many People Have Already Volunteered VANCOUVER, Washington, Nov. 17, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company de...

CYDY - CytoDyn receives Canadian approval to file application for leronlimab as combination therapy for HIV

Health Canada has cleared CytoDyn (CYDY) to file its Biologics License Application ((BLA)) for leronlimab as a combination therapy for multi-drug resistance HIV patients in Canada. The BLA filing includes a treatment regimen of one injection per week of 350 mg of leronlimab, as contrasted to ...

CYDY - CytoDyn Announces Registration of Trademark for VYROLOGIX in Several Countries

Vyrologix is the proprietary name for leronli ma b VANCOUVER, Washington, Nov. 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagoni...
CYDY - Health Canada Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy

VANCOUVER, Washington, Nov. 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...

CYDY - CytoDyn secures $28.5M in convertible debt

CytoDyn (CYDY) has completed an additional non-dilutive convertible debt offering with an institutional investor, and provides $25M of immediately available capital. The note has a two-year maturity, bears annual interest rate of 10%. Conversion price for the note is $10/share.The company say...

CYDY - CytoDyn Completes Second Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Help Expedite License Applications Here and Abroad and Successful COVID-19 Trials

VANCOUVER, Washington, Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...
Previous 10 Next 10